Plus Therapeutics, Inc. (Nasdaq: PSTV) ('Plus” or the 'Company”), a healthcare company developing and commercializing ...

Scientists at the University of Warwick have developed a fully fibre-coupled terahertz (THz) imaging system that ...

The raised price target from $8 to $12 puts Insight Molecular Diagnostics more firmly on the radar for investors tracking valuation shifts. Analysts are linking this higher price target to the recent ...

Cleveland-based University Hospitals recorded an operating income of $191.8 million (2.6% operating margin) in 2025, up from an operating loss of $172.6 million (-2.7% margin) in 2024, according to ...

Ibex Medical Analytics has signed a strategic partnership with HNL Lab Medicine to deploy clinical-grade AI for prostate ...

Aims to improve quality of care for patients with Alzheimer's disease… Exploring adoption of Neurophet's key ...

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today ...

Imagine a late-winter Wednesday morning in a rural Prince Edward Island clinic. Because it takes some time for the heat to catch up with the cold outside, the waiting room can accommodate about eight ...

Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2025 Earnings Call Transcript March 26, 2026 Lucid Diagnostics Inc. misses on earnings expectations. Reported EPS is $-0.1 EPS, expectations were $-0.07.

VASCADE MVP XL now approved for larger sheaths used in market-leading PFA and LAAC technologies BOSTON, March 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology ...

Tempus AI's integrated genomic and clinical data flywheel creates a defensible moat. Read why I'm rating TEM stock a Strong ...

From the importance of looking up ailments to the comfort and cleanliness of hospitals, Roland Bull has experienced both sides of the bed as a patient-turned-doctor ...